pegcantratinib

05/01/2015 - "We report the efficacy of a TrkA inhibitor, CT327, on pruritus in psoriasis. "
05/01/2015 - "Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis."

05/01/2015 - "TrkA is a key target in pruritus, and CT327 has potential to become an effective and safe first-in-class treatment."
05/01/2015 - "We report the efficacy of a TrkA inhibitor, CT327, on pruritus in psoriasis. "
05/01/2015 - "Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis."

01/01/2018 - "In this study, pegcantratinib, 0.5% (wt/wt), applied once daily appeared to be well tolerated and to penetrate the tumor tissue; however, the low tumor drug concentrations demonstrated are likely to account for the lack of response. "
01/01/2018 - "In phase 2a (15 patients [13 female; median age, 51 years], with 150 tumors), 2 tumors treated with pegcantratinib achieved the primary outcome measure of response compared with 6 tumors treated with placebo. "
01/01/2018 - "The primary outcome measure was the number of tumors meeting the criteria for response in a prespecified critical number of pegcantratinib-treated tumors. "
01/01/2018 - "Patients were eligible if they had 10 small skin tumors, with 5 matched lesions on each body side; patients were randomized to receive active treatment (pegcantratinib) to one body side and placebo to the other side once daily for 12 weeks. "
01/01/2018 - "In phase 1b, patients with CCS applied pegcantratinib for 4 weeks to a single skin tumor. "